CN1903860A - Technology of preparing high purity cefotamei sodium by solvent process and its medical use - Google Patents
Technology of preparing high purity cefotamei sodium by solvent process and its medical use Download PDFInfo
- Publication number
- CN1903860A CN1903860A CN 200510021319 CN200510021319A CN1903860A CN 1903860 A CN1903860 A CN 1903860A CN 200510021319 CN200510021319 CN 200510021319 CN 200510021319 A CN200510021319 A CN 200510021319A CN 1903860 A CN1903860 A CN 1903860A
- Authority
- CN
- China
- Prior art keywords
- cefetamet
- high purity
- acid
- sodium
- washed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The present invention relates to a process for preparing high-purity cefetamet sodium (6R.7R)-3-methyl-7-[(2-amino-4-thiazolyl)-(methoxyimino)-acetylamino]-8-keto-5-thia-1-azadicyclo[4,2,0]-octo-2-alkene-2-sodium carboxylate by using solvent method and its medicine application for preparing injection.
Description
Technical field
The present invention relates to Ro 15-8074/001 (6R, 7R)-3-methyl-7-[(2-amino-4-thiazolyl)-(methoxyimino)-kharophen]-the solvent method preparation method of 8-oxo-5-thia-1-azabicyclo [4,2,0]-oct-2-ene-2-carboxylic acid sodium.
Background technology
Since cephalo thiophene (Cephalothin) in 1964 appearance, cephalosporins medicine obtains flourish, so far kind of a medicine is is worldwide produced and sold surplus in the of existing 50, directly treating most of bacterial infection patients, as third generation oral cephalosporin class medicine---Ro 15-8075 (Cefetamet PivilHydrochloride, molecular formula C
20H
25N
5O
7HCl) be that Japanese military field Pharma Inc. and Switzerland Roche company research and develop jointly, in 1992 at first list marketing of Mexico, its mechanism of action be oral enter gi tract after, in enteron aisle, become the acid of active body cefetamet (Cefetamet Acid, molecular formula: C through esterase hydrolyzed
14H
15N
5O
5S
2) and the performance anti-microbial effect, cefetamet acid has anti-microbial effect widely to gram-positive microorganism, Gram-negative bacteria etc., particularly to the streptococcus pneumoniae in the gram-positive microorganism, streptococcus pyogeness etc. have very strong antimicrbial power, very stable to the multiple β-Nei Xiananmeis such as cephalosporinase that aerophil and anerobe produced, be the anti-infective oral pharmaceutical of widespread use clinically.
Yet in the clinical application, find that there is following shortcoming in this medicine: 1) this medicine is owing to be oral, and poorly water-soluble, and the artifact availability that causes taking medicine is poor, and absolute bioavailability is no more than 50%, and rest part is excreted, and causes significant wastage; 2) this medicine is the ester dissolubility, can't make injection and use; 3) can't use these product to the urgent patient owing to oral difficulty; 4) in the preparation process, complex process, yield is low, and the foreign matter content height is difficult for eliminating.In sum, further prepare highly purified Ro 15-8074/001 thereby prepare the acid of highly purified cefetamet, but exploitation injection Ro 15-8074/001, i.e. one of urgent problem now.
Summary of the invention
The invention provides and a kind ofly accomplish to provide highly purified cefetamet acid by improving existing preparation technology, and be raw material with highly purified cefetamet acid, prepare highly purified Ro 15-8074/001, but and then make injection only contain the cefetamet preparation of sodium that Ro 15-8074/001 does not contain other assistant agent, overcome Ro 15-8075 oral preparations defective commonly used, thereby make it become novel clinical application product.
The structural formula of highly purified cefetamet acid of indication of the present invention and Ro 15-8074/001 is as follows respectively:
Popular name: cefetamet acid
Chemical name: (6R, 7R)-3-methyl-7-[(2-amino-4-thiazolyl)-(methoxyimino)-kharophen]-8-oxo-5-thia-1-azabicyclo [4,2,0] oct-2-ene-2-carboxylic acid
Popular name: Ro 15-8074/001
Chemical name: (6R, 7R)-3-methyl-7-[(2-amino-4-thiazolyl)-(methoxyimino)-kharophen]-8-oxo-5-thia-1-azabicyclo [4,2,0]-oct-2-ene-2-carboxylic acid sodium
The preparation method of high-purity cefetamet acid of the present invention be in organic solvent such as alcohols, acetone or the water with organic bases as diethylamine, triethylamine, tert-butyl amine or mineral alkali such as sodium bicarbonate, the cefetamet acid that makes low-purity under cold condition as: 0 ℃～～-30 ℃, be preferably-5 ℃～～-25 ℃ following crystallizations, become the salt of organic bases or mineral alkali to be separated, again under the water condition and mineral acid as neutralizations such as sulfuric acid, nitric acid, hydrochloric acid and acetic acid, isoelectric point crystallizing obtains the acid of high purity cefetamet, after testing its HPLC method chromatographic purity 〉=99.5%; With above-mentioned high purity cefetamet acid organic solvent dissolution, with salt forming agent as sodium bicarbonate and triethylamine salify and make the high purity Ro 15-8074/001, its HPLC method chromatographic purity 〉=99.0% after testing.
Also can with above-mentioned both in conjunction with single stage method from the highly purified Ro 15-8074/001 of low-purity cefetamet acid preparation: promptly organic phase under proper temperature with organic bases or the dissolving of mineral alkali salify, salt forming agent salify and make the high purity Ro 15-8074/001.
HPLC method chromatographic purity 〉=99.5% of the cefetamet acid that the present invention makes,
HPLC method chromatographic purity 〉=99.0% of the Ro 15-8074/001 that the present invention makes,
Ro 15-8074/001 of the present invention is the unformed powder of white or off-white color, and is soluble in water, is slightly soluble in alcohol, is insoluble to acetone, content in cefetamet acid in (dry product calculating) more than 94%
Because its purity of highly purified Ro 15-8074/001 that makes is more than 99.0%, foreign matter content significantly reduces, and can dissolve easily in water, and need not to add solubility promoter and just can be made into the injection that only contains Ro 15-8074/001.Meet 2005 editions Chinese Pharmacopoeia requirements through its solubleness of evidence and clarity.
Description of drawings
Fig. 1 cefetamet acid HPLC figure
Fig. 2 cefetamet acid HPLC figure
Fig. 3 cefetamet acid HPLC figure
Fig. 4 cefetamet acid---triethylamine salt HPLC figure
Fig. 5 cefetamet acid---triethylamine salt α-powder diagram
Fig. 6 cefetamet acid---triethylamine salt HPLC figure
Fig. 7 cefetamet acid---triethylamine salt α-powder diagram
Fig. 8 Ro 15-8074/001 HPLC figure
Fig. 9 Ro 15-8074/001 HPLC figure
The amorphous Ro 15-8074/001 X-of Figure 10 ray powder figure
Embodiment
Below again foregoing of the present invention is described in further detail by embodiment the synthetic example of some particular compound.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
Get cefetamet acid 60.0g (HPLC purity 97.5%), add pure water 480ml, stirring suspension is in below 10 ℃, add the dissolving of 15.24g sodium bicarbonate, gac 3g decolouring is filtered, washing charcoal layer, diafiltration liquid merges, transfer pH=1.5-3.0 with 4N hydrochloric acid, heavyization of crystallization two hours filtered, washing, vacuum-drying gets the acid of 57.6g cefetamet.HPLC purity 99.39% (see figure 1)
Get 60.0g cefetamet acid (HPLC 97.5%) and add 500ml ethanol, the frozen water cooling is when interior temperature is lower than 15 ℃, add triethylamine 30ml, stirred crystallization is filtered, a little Virahol is washed, after draining crystallization is dissolved in the 450ml pure water, transfers pH=1.5-3.0, heavyization with 4N hydrochloric acid, filter, wash, vacuum-drying gets cefetamet acid 53.0g, HPLC purity: 99.64% (see figure 2)
Get 60.0g cefetamet acid (HPLC 97.5%) and add 500ml acetone, the frozen water cooling is when interior temperature is lower than 15 ℃, add triethylamine 30ml, stirred crystallization is filtered, a little acetone is washed, after draining crystallization is dissolved in the 450ml pure water, transfers pH=1.5-3.0, heavyization with 4N hydrochloric acid, filter, wash, vacuum-drying gets cefetamet acid 51.5g, and HPLC 99.57%.(see figure 3)
Get 60.0g cefetamet acid (HPLC 97.5%) and add 500ml ethanol, the frozen water cooling, when interior temperature is lower than 15 ℃, add triethylamine 30ml, stirred crystallization is filtered the crystallization in the organic phase, the washing after drying, promptly get crystal type cefetamet acid-triethylamine salt 64.0g, its HPLC purity: 99.72%.
Molecular formula is: C
14H
15N
5O
5S
2N (C
2H
5)
3, see Fig. 4 and Fig. 5.
Get 60.0g cefetamet acid (HPLC 97.5%) and add 500ml acetone, the frozen water cooling when interior temperature is lower than 15 ℃, adds triethylamine 30ml, stirred crystallization is filtered, washing, drying, get 66.0g crystal type cefetamet acid-triethylamine, its HPLC purity is 99.58%, sees Fig. 6; X-ray powder figure sees Fig. 7.
The preparation method 1 of embodiment 6 aseptic high purity Ro 15-8074/001s
50g cefetamet acid (purity is more than 99.5%) in pure water 100ml, is suspended among the ethanol 100ml, add sodium bicarbonate and make dissolving, gac 50g decolouring, elimination charcoal layer is crossed in the desuperheating source, a little 1: 1 water-Virahol is washed, and the sterile filtration of diafiltration liquid is in sterilisable chamber, add Virahol 3.5L stirred crystallization, and be cooled to-20 ℃～～-25 ℃, crystallization is more than 10 hours, filter, acetone is washed, aseptic drying, get aseptic unformed high purity Ro 15-8074/001 45.8g, HPLC purity 99.64% (see figure 8)
The preparation method 2 of embodiment 7 aseptic high purity Ro 15-8074/001s
With the acid of 60.0g cefetamet, be suspended in the 450ml ethanol, add triethylamine 30ml and make its dissolving, the room temperature decolouring is filtered, and ethanol is washed, sterile filtration is stirred in sterilisable chamber down and is dripped Sodium isooctanoate/ethanol liquid (its concentration is 10%) 300ml, dropwises in one hour, frozen water cooled off 2 hours down for outer-5 ℃～～-10 ℃, filtered, and ethanol is washed, aseptic drying gets aseptic unformed high purity Ro 15-8074/001 49.5g, HPLC purity 99.74%, see Fig. 9, Figure 10.
| Sample number into | 1 | 2 | 3 | 4 | 5 | 6 |
| Sample size (gram) | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 |
| The water yield (ml) | 0.5 | 1.0 | 2.0 | 3.0 | 4.0 | 5.0 |
| The dissolving situation | Not molten entirely | Molten entirely | Molten entirely | Molten entirely | Molten entirely | Molten entirely |
Test-results shows that its solubleness is fabulous.
| Sample number into | 1 | 2 | 3 | 4 | 5 | 6 |
| Sample size (gram) | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 |
| The water yield (ml) | 0.5 | 1.0 | 2.0 | 3.0 | 4.0 | 5.0 |
| Clarity ※※ | - | ＜1 # | ＜1 # | ＜1 # | ＜0.5 # | ＜0.5 # |
Test-results shows: according to the requirement of 2005 editions relevant cynnematin veriety defineds of Chinese Pharmacopoeia, its clarity (turbidity) requirement should be less than 1
#Turbidity standard meets the requirements.
※ ※Clarity is to require preparation 1 with Chinese Pharmacopoeia 2005 editions
#, 0.5
#Turbidity standard compares.
By the aseptic Ro 15-8074/001 of gained among the embodiment 6,7, under aseptic subpackaged line, carry out packing, loading amount is pure product Ro 15-8074/001 (in the cefetamet acid) 1g in each cillin bottle, 0.5g, 0.25g.
Experimental example 1 activity test in vitro
Adopt the agar doubling dilution to measure the vitro antibacterial activity of injection Ro 15-8074/001 (cefetamet sodium) to clinical separation 363 strain pathogenic bacterium, and to the interior curative effect of mouse infection bacterium, and compare with similar microbiotic ceftriaxone, Cefaclor, cefmenoxime and the husky star of present clinical common antibiotics left side oxygen, netilmicin.The antibacterial activity in vitro of injection cefetamet studies show that it all has the strong and weak anti-microbial activity that does not wait to most of bacterial strain of being tested, and MIC value scope is mostly at 1-〉128ug/ml, the antibiotic vigor of gram-negative bacteria is better than gram positive organism.
The in-vitro antibacterial test-results shows: Ro 15-8074/001 and control drug ceftriaxone sodium, Cefaclor, cefmenoxime, the husky star of left oxygen, netilmicin are to the MIC of the common staphylococcus aureus in the gram-positive microorganism of being tested, MSSA, MRSA
50Value is respectively 16,8,32,4,1,0.5ug/ml; 1,0.25,64,＞128,32,0.25ug/ml; 32,2,1,0.5,0.06,0.25ug/ml.MIC to MRSE, MSSE
50Value is 8,4,4,1,0.125,0.06ug/ml; 8,2,0.125,0.125,0.06,0.03ug/ml.MIC to micrococcus scarlatinae, streptococcus pneumoniae
50Value is 1,0.25,1,0.06,0.5 respectively, 0.25ug/ml and 1,0.25,2,0.125,0.25,0.5ug/ml.
Cefetamet and control drug ceftriaxone sodium, Cefaclor, cefmenoxime, the husky star of left oxygen, netilmicin are better to the antibacterial activity in vitro of the escherichia coli in the Gram-negative bacteria of being tested, Cray uncle pulmonitis strain, proteus vulgaris, Acinetobacter bauamnnii, pseudomonas aeruginosa, catarrh Blanc Chinese bacterium, MIC
50Value respectively is 1,1,8,0.5,16,1ug/ml; 1,0.125,12 8,0.125,0.125,2ug/ml; 2,8,128,4,0.5,2ug/ml; 8,4,16,8,0.03,1ug/ml; 4,1,2,4,0.5,4ug/ml; 4,2,0.5,0.5,0.06,2ug/ml.To other Gram-negative bacterias of testing, the MIC scope of cefetamet is mostly at 1-128ug/ml.To product extended spectrum (ESBL strain) escherichia coli and the Klebsiella Pneumoniae tested, cefetamet shows than the better antibacterial activity in vitro of control drug, and cefetamet and control drug are to the MIC of these two kinds of bacterial strains
50Value is respectively 64,64,＞128,64,8,8ug/ml and 16,64,128,32,2,32ug/ml.
The endogenous protective test-results shows: Ro 15-8074/001 all has the endogenous protective effect to streptococcus aureus 05-2, streptococcus pneumoniae 05-16 and escherichia coli ESBL05-10 infecting mouse, to the ED of these 3 kinds of clinical bacteria infecting mouses
50Be respectively 20.73mg/kg, 14.64mg/kg.
Ro 15-8074/001 is to the median protective dose ED of streptococcus aureus 05-2 infecting mouse
50(20.73mg/kg) all not as other control drug, Cefaclor, cefmenoxime, ceftriaxone, the husky star of left oxygen and netilmicin are to the ED of this strain infection mouse
50Be respectively 15.39mg/kg, 9.18mg/kg, 9.93mg/kg, 3.96mg/kg and 1.99mg/kg.
Ro 15-8074/001 is to the median protective dose ED of streptococcus pneumoniae 05-16 infecting mouse
50(14.64mg/kg) suitable with several cephalosporin analog antibiotics, Cefaclor, cefmenoxime, ceftriaxone are to the ED of this strain infection mouse
50Be respectively 15.68mg/kg, 17.30mg/kg, 13.56mg/kg; But not as while husky star of quinolone antibiotic left side oxygen and netilmicin in contrast, they are to the median protective dose ED of streptococcus pneumoniae 05-16 infecting mouse
50Be respectively 2.00mg/kg and 2.33mg/kg.
Experimental example 2 acute toxicity tests
This test adopts fixed dosage test method and mtd test method that injection Ro 15-8074/001 single-dose toxicity is studied.
It is pilot system that the fixed dosage test method is selected SPF level SD rat for use, with the administration of 2000mg/kg dosage single tail vein injection, behind the animals administer at once with the observation cycle in, both do not found the unusual of general behavior, do not find any unusual symptom yet.Test-results shows that under this test conditions, SD rat tail vein single injection Ro 15-8074/001 does not have the danger that serious acute is poisoned.
It is pilot system that the mtd test method is selected SPF level KM mouse for use, with 5000, the administration of 2000mg/kg dosage single tail vein injection.At once have a convulsion behind all animals administers of 5000mg/kg dosage group, be the shape of lying on one's side; Wherein a part of animal dead, dead animal did not recover normal in 30 minutes.At once do not occur any unusual behind all animals administers of 2000mg/kg dosage group.Test-results shows that under this test conditions, the maximum tolerated dose of KM mouse single tail vein injection Ro 15-8074/001 is not less than 2000mg/kg, is equivalent to clinical plan 20 times with dosage.
The test of experimental example 3 animal pharmacokinetics
15 healthy Beagle dogs are divided into 3 groups at random, every group 5, male and female all have, intravenous injection 7.5,30 respectively, 600mg/kg injection Ro 15-8074/001 are (if press the body surface area conversion, be equivalent to 0.5,2,40 times of human clinical dosage respectively) after, its pharmacokinetic parameters is respectively: Cmax 38.8,113.4,5.04ug/ml, t
1/2 β0.86,1.31,1.43h, V 0.153,0.221,0.284L/kg, CL/F 0.160,0.203,0.220L/kg/h.AUC 53.2,162.6,2883.7ug/ml*h in the 12h, through the match of 3p97 program, cefetamet meets two Room open models in the intravital characteristics of pharmacokinetics of Beagle dog.
180 rats are divided into 36 groups (every groups 12 blood sampling time point * 3 group) at random, every group 5, male and female all have, intravenous injection 50,100 respectively, 1000mg/kg injection Ro 15-8074/001 are (if press the body surface area conversion, be equivalent to 1,2,20 times of human clinical dosage respectively) after, its pharmacokinetic parameter is respectively: Cmax 66.7,216.9,1972.7ug/ml, t
1/2 β1.49,1.36,1.27h, V 0.606,0.448,0.466L/kg, CL/F 0.409,0.41 3,0.396L/kg/h.AUC 129.1,293.1,2627.3ug/ml*h in the 12h, through the match of 3p97 program, cefetamet also meets two Room open models in its pharmacokinetics in rats feature.
Rat intravenous injection 100mg/kg injection cefetamet is (if press the body surface area conversion, be equivalent to 2 times of human clinical dosage) after, during 1h in the tissue cefetamet concentration the highest, take second place during 4h, 8h is minimum, during 8h in the tissue cefetamet dose oneself almost from tissue, remove fully, point out this medicine in tissue, not have accumulating.The concentration of cefetamet in each tissue is followed successively by kidney, liver, lung, stomach, the heart, skeletal muscle, spleen, small intestine, fat, brain and sexual gland (testis or ovary) from high to low during 1h, though wherein the concentration of cefetamet in nephridial tissue is the highest, but also only be about 1.5 times with the time serum-concentration, it is feasible pointing out this medicine to change intravenous injection into from oral route, also should be safe.
According to bibliographical information, prodrug-the Ro 15-8075 of oral cefetamet after intestinal absorption and very fast be that cefetamet shows anti-microbial activity by the esterase hydrolyzed of intestines wall, 90% cefetamet is discharged from urine with original shape in vivo, and discharges in 24h and finish.
According to bibliographical information, the serum protein combination rate of cefetamet is 22%.
Experimental example 4 injection Ro 15-8074/001 repetitively administered toxicity tests
1, injection Ro 15-8074/001 rat repetitively administered toxicity test
Under the GLP experiment condition of this center, in the barrier system, 120 SD rats are divided into 4 groups, male and female half and half, 30/group, respectively tail vein injection injection Ro 15-8074/001 160,400, three dosage of 1000mg/kg/d (calculate 3.2,8 and 20 times that are equivalent to respectively to intend with clinical dosage by the equivalent surface-area, calculate 20,50 and 125 times that are equivalent to respectively to intend with clinical dosage by kg body weight) and physiological saline, continuous 4 weeks.After the last administration 24 hours, handle 20 of rats for every group, male and female half and half, routine blood test, blood clotting, biochemical indicator and ionogen index are checked in the aorta abdominalis blood sampling, do system's postmortem, get 12 internal organs calculating organ coefficient of weighing, 30 internal organs are done the pathology inspection.The drug withdrawal of residue animal observed for 2 weeks as decubation, put to death then and did as above all index detections.
Under this experiment condition, rat continuous 4 all intravenous injection injection Ro 15-8074/001 1000mg/kg/d (calculate 20 times that are equivalent to clinical dosage by the equivalent surface-area, calculate 125 times that are equivalent to clinical dosage by kg body weight) can cause rat body weight to reduce, metabolism is vigorous, anaemia, malnutrition and renal dysfunction, the target organ of poisoning is a kidney.Substantially recover normal in the drug withdrawal 2 week above-mentioned untoward reaction in back.Middle dosage (400mg/kg/d) and low dose group (160mg/kg/d) rat do not see that overt toxicity changes.The safe dose of no toxic side effects is≤400mg/kg/d (calculate 8 times that are equivalent to clinical dosage by the equivalent surface-area, calculate 50 times that are equivalent to clinical dosage by kg body weight).
2, injection Ro 15-8074/001 dog repetitively administered toxicity test
Under the GLP experiment condition of this center, in the open system, 24 Beagle dogs are divided into 4 groups, male and female half and half, 6/group, respectively intravenous drip injection Ro 15-8074/001 96,240, three dosage of 600mg/kg/d (calculate 6.4,16 and 40 times that are equivalent to respectively to intend with clinical dosage by the equivalent surface-area, calculate 12,30 and 75 times that are equivalent to respectively to intend with clinical dosage by kg body weight) and physiological saline, continuous 4 weeks.Observe the outward appearance symptom every day; Weigh weekly once; Respectively at before the administration, 2 weeks of administration, administration end and recovered for 2 weeks after respectively survey routine urinalysis and Electrocardioscopy; Before the administration, 2 weeks of administration, administration end and recovered for 2 weeks after respectively do blood and blood biochemistry checking.After the last administration 24 hours, handle 3 of dogs for every group, dissect, do system's postmortem, get 12 internal organs calculating organ coefficient of weighing, 30 internal organs are done the pathology inspection.The drug withdrawal of residue animal observed for 2 weeks as decubation, put to death then and did as above all index detections.
Under this experiment condition, three dosage of Beagle dog continuous 4 all intravenous drip injection Ro 15-8074/001s do not see that overt toxicity changes, and unusual index and dosage are not proportionate, and all recover normal after decubation.The safe dose of no toxic side effects is≤600mg/kg/d (calculate 40 times that are equivalent to clinical dosage by the equivalent surface-area, calculate 75 times that are equivalent to clinical dosage by kg body weight).
Experimental example 5 injection Ro 15-8074/001 security pharmacological testings
Large and small mouse vein, abdominal injection give the injection Ro 15-8074/001, dosage is 200,400 respectively, 800mg/kg, be clinical plan 25 times, 50 times and 100 times with dosage, the influence and the rat coordinated movement test of mouse autonomic activities, pentobarbital sodium sub-threshold lull dosage have been carried out, result and control group compare, and the injection Ro 15-8074/001 does not all have obvious influence to mouse autonomic activities, mouse pentobarbital sodium sub-threshold lull dosage and rat coordinated movement.Beagle dog intravenous injection injection Ro 15-8074/001 40mg/Kg (clinical plan is with 5 times of dosage) observed 4 hours after the administration, and its general behavioral activity is no abnormal.Show that the injection Ro 15-8074/001 does not have obvious influence to the neural psychiatric system of large and small mouse and dog.
Beagle dog intravenous injection injection Ro 15-8074/001, dosage are 400mg/kg (clinical plan is with 50 times of dosage), carry out anesthetized dog breathing, blood pressure, Electrocardiographic observation.Do not find that the injection Ro 15-8074/001 has a significant effect to dog breathing, blood pressure and electrocardiogram(ECG.
Experimental example 6 injection Ro 15-8074/001 genetic toxicity tests
1, injection Ro 15-8074/001 mouse bone marrow cells micronucleus test
This test is a laboratory animal with the NIH small white mouse, and the injection Ro 15-8074/001 has been carried out female, male mice bone marrow micronucleus test.Test design dosage is 2000mg/kg, 1000mg/kg and 500mg/kg (pressing the body surface area conversion, is respectively 28,14 and 7 times of clinical dosage), and abdominal injection (ip) administration is administered once; (endoxan, dosage 50mg/kg's positive controls ip), are administered once.Animal is put to death in the dislocation of 24 hours cervical vertebras after the administration, gets the femur bone marrow film-making, count in 200 polychromatic erythrocytes and the normocyte they ratio and 1000 polychromatic erythrocytes in micronucleated cell set.With the SPSS statistical software each group data is carried out statistical study.
This experimental result shows that contaminate each dosage group microkernel incidence and negative control group relatively do not have significant difference (P＞0.05), and positive controls microkernel incidence and negative control group relatively have utmost point significant difference (P＜0.01).Test is respectively organized the ratio of PCE and NCE all in range of normal value.Test-results shows that under this testing laboratory condition, DADS does not have the PCE of bringing out micronucleus rising effect to mouse, and promptly test-results is negative.
2, the injection Ro 15-8074/001 is cultivated chromosomal aberration test to the CHL cells in vitro
Test is a target cell with hamster pneumonocyte strain (CHL), with its mitosis metaphase phase karyomit(e) be detected object, 5 dosage are established in test.Its dosage design considerations CHL cell half growth inhibitory concentration (IC50) test result, selecting the dosage near IC50 concentration for use is maximum dose level, establishes 5 dosage groups with geometric ratio, promptly 500,250,125,62.5,31.25mg/ml.Other establishes positive controls (disactivation positive control mitomycin MMC0.5 μ g/ml and activation positive control endoxan CP50 μ g/ml) and solvent control group (physiological saline).Do not add-24,48 hours and 24 hours three kinds of chromosome specimens that add S9mix of S9mix.Sample is carried out observing under the mirror,, judge whether trial-product has the effect of bringing out the mammalian cell chromosome aberration according to rate of cell with chromosome aberration.Test-results shows: trial-product 24 hours and 48 hours non-metabolism activation methods (S9mix) and 24 hours metabolism activation methods (+S9mix) all negative.Positive control MMC, CP aberration rate all＞20%, and negative solvent control is all＜5%, shows that test macro meets test request.In sum, test-results shows that this trial-product is negative to hamster pneumonocyte strain chromosome aberration fall out effect.
3, the injection Ro 15-8074/001 is to mouse lymphoma cell L5178Ytk gene mutation test
Test employing mouse lymphoma cell L5178Ytk+/-3.7.2c clone, begin according to the determined maximum dose level of solubility test, with 2 times of extent of dilution to dividing into 6-10 dosage, carry out toxotest, determine cytotoxicity with relative overall growth rate (RTG) by the relative survival rate (RS) that calculated the 0th day.Select the maximum dose level of 10%-20%RSG as mutagenesis testing, and with 2 times of extent of dilution to dividing into 2-5 dosage.Mouse lymphoma cell is exposed to trial-product under activation or disactivation condition, handled the back the 2nd day, and cell inoculation in 96 orifice plates that contain sudden change selective agent trifluorothymidine, is counted the mutant cell colony number of each dosage group.Test-results shows that under non-metabolism activation and metabolism activation condition, each dosage group trial-product does not see that the mutation rate of inducing mouse lymphoma L5178Y cell increases.Positive control inductive mutation rate significantly increases.Therefore, each dosage group of this trial-product does not have mutagenesis to mouse lymph lymphoma L5178Y cell TK gene.
Experimental example 7 Ro 15-8074/001 rat critical porion reproductive toxicity tests
Being subjected to reagent Ro 15-8074/001 SD rat critical porion genotoxicity intravenous administration dosage is 500mg/kg and 1000mg/kg (be equivalent to clinical plan consumption 5 times and 10 times), at SD pregnant rat sensitive period of teratogenesis intravenously administrable, other establishes physiological saline control group and positive controls (destomycins 8mg/kg), female mouse is checked indexs such as corpus luteum number, uterus implantation, the young absorption of tire, outward appearance, internal organ and skeleton development in gestation the 20th heaven-made c-section.
Experimental result shows: high dose group (1000mg/kg) pregnant rat body weight occurred by the reaction of maternal toxicities such as slight inhibition; Every index of low dose group (500mg/kg) and control group are not seen notable difference; Positive controls has more existing weight loss, the embryo absorbs phenomenons such as many, that stillborn foetus is many; Be subjected to the young outward appearance no abnormality seen of each dosage group tire of reagent; Teratogenesis phenomenons such as dysostosis, breastbone counterincision appear in the young majority of positive controls tire, and internal organ through Ro 15-8074/001 respectively being organized the tire son and bone studies show that relatively no significant difference of its internal organ and skeleton development and control group.
Above-mentioned result of study shows: under this experiment condition, intravenous injection Ro 15-8074/001 500mg/kg and 1000mg/kg (be equivalent to clinical plan consumption 5 times and 10 times), the high dosage pregnant rat there is maternal toxicity, show as phenomenons such as weight loss, low dose group pregnant rat and physiological saline control group are not seen notable difference, the young outward appearance of each dosage group tire of Ro 15-8074/001, internal organ and skeleton development there is no the deformity relevant with administration, do not see that promptly Ro 15-8074/001 has obvious teratogenesis.
Experimental example 8 supersensitivity, hemolytic, pungency proof test
This test adopts fixed dosage test method and mtd test method that injection Ro 15-8074/001 single-dose toxicity is studied.
It is pilot system that the fixed dosage test method is selected SPF level SD rat for use, with the administration of 2000mg/kg dosage single tail vein injection, behind the animals administer at once with the observation cycle in, both do not found the unusual of general behavior, do not find any unusual symptom yet.Test-results shows that under this test conditions, SD rat tail vein single injection Ro 15-8074/001 does not have the danger that serious acute is poisoned.
It is pilot system that the mtd test method is selected SPF level KM mouse for use, with 5000, the administration of 2000mg/kg dosage single tail vein injection.At once have a convulsion behind all animals administers of 5000mg/kg dosage group, be the shape of lying on one's side; Wherein a part of animal dead, dead animal did not recover normal in 30 minutes.At once do not occur any unusual behind all animals administers of 2000mg/kg dosage group.Test-results shows that under this test conditions, the maximum tolerated dose of KM mouse single tail vein injection Ro 15-8074/001 is not less than 2000mg/kg, is equivalent to clinical plan 20 times with dosage.
Claims (7)
1, a kind of method of preparing high purity cefotamei sodium by solvent process, its processing step is as follows:
A) cefetamet acid is placed organic solvent, the frozen water cooling when interior temperature is lower than 15 ℃, adds organic bases, and stirred crystallization is filtered, and a little Virahol is washed, and gets cefetamet acid-organic alkali salt crystallization after draining;
B) cefetamet acid-organic alkali salt crystallization is dissolved in the pure water, transfers pH with 4N hydrochloric acid, heavyization filtered, washed, and vacuum-drying gets the acid of high purity cefetamet;
C) with the acid of high purity cefetamet, be suspended in the organic solvent, add organic bases and make its dissolving, decolouring is filtered, and ethanol is washed, sterile filtration, in sterilisable chamber, stir down and drip the Sodium isooctanoate salify, dropwise in one hour, filter, organic solvent is washed, aseptic drying gets aseptic unformed high purity Ro 15-8074/001, HPLC purity 99.74%.
2, the method for preparing the high purity Ro 15-8074/001 as claimed in claim 1 is characterized in that: its organic solvent can be ethanol and acetone.
3, the method for preparing the high purity Ro 15-8074/001 as claimed in claim 1 is characterized in that: its organic bases can be triethylamine, diethylamine or tert-butyl amine.
4, a kind of method of preparing high purity cefotamei sodium by solvent process, its processing step is as follows:
A) cefetamet acid is placed pure water, stirring suspension adds the sodium bicarbonate dissolving, activated carbon decolorizing in below 10 ℃, filter, washing charcoal layer, diafiltration liquid merges, and transfers pH with 4N hydrochloric acid, heavyization of crystallization two hours filtered, washing, and vacuum-drying gets the acid of high purity cefetamet.
B) acid of high purity cefetamet is placed pure water 100ml, suspend among the ethanol 100ml, add sodium bicarbonate and make dissolving, gac 50g decolouring, elimination charcoal layer is crossed in the desuperheating source, a little 1: 1 water-Virahol is washed, and the sterile filtration of diafiltration liquid is in sterilisable chamber, add the Virahol stirred crystallization, and be cooled to-20 ℃～～-25 ℃, crystallization is more than 10 hours, filter, acetone is washed, aseptic drying, get aseptic unformed high purity Ro 15-8074/001, HPLC purity 99.64%.
5, as claim 1 or the 4 described methods that prepare the high purity Ro 15-8074/001, it is characterized in that: transferring pH with 4N hydrochloric acid is 1.5-3.0.
6, the purposes of a kind of high purity Ro 15-8074/001 in preparation injection cefetamet preparation of sodium is characterized in that said preparation only contains the high purity Ro 15-8074/001, does not contain other assistant agent.
7, the purposes of preparation injection cefetamet preparation of sodium as claimed in claim 6 is characterized in that the specification of preparation is 1g for the high purity Ro 15-8074/001 loading amount in each cillin bottle, 0.5g, 0.25g (in cefetamet acid).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100213193A CN1903860B (en) | 2005-07-25 | 2005-07-25 | Technology of preparing high purity cefotamei sodium by solvent process and its medical use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100213193A CN1903860B (en) | 2005-07-25 | 2005-07-25 | Technology of preparing high purity cefotamei sodium by solvent process and its medical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1903860A true CN1903860A (en) | 2007-01-31 |
| CN1903860B CN1903860B (en) | 2012-01-18 |
Family
ID=37673240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100213193A Expired - Fee Related CN1903860B (en) | 2005-07-25 | 2005-07-25 | Technology of preparing high purity cefotamei sodium by solvent process and its medical use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1903860B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101550147B (en) * | 2009-05-07 | 2011-05-04 | 郑仙锋 | Cefdinir compound and preparation method thereof |
| CN104327098A (en) * | 2014-10-21 | 2015-02-04 | 鲁南制药集团股份有限公司 | Cefetamet hydrochloride diisopropylamine salt |
| CN110143972A (en) * | 2018-02-12 | 2019-08-20 | 罗欣药业(上海)有限公司 | A kind of Cefazedone sodium novel crystal form and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL178231B1 (en) * | 1995-01-31 | 2000-03-31 | Pan | Pharmaceutic injection mould and method of making same |
| AT405283B (en) * | 1997-04-04 | 1999-06-25 | Biochemie Gmbh | NEW CRYSTALLINE 7- (Z) - (2- (2-AMINOTHIAZOL-4-YL) -2-HYDROXYIMINOACETAMIDO) -3-VINYL-3-CEPHEM-4- CARBONIC ACID DICYCLOHEXYLAMMONIUM SALTS AND METHODS FOR THE PRODUCTION THEREOF |
| CN100381445C (en) * | 2003-11-05 | 2008-04-16 | 余安国 | Cefetamet sodium and its application of preparing powder injection or dry powder injection for broad-spectrum strong antibiotic injection |
-
2005
- 2005-07-25 CN CN2005100213193A patent/CN1903860B/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101550147B (en) * | 2009-05-07 | 2011-05-04 | 郑仙锋 | Cefdinir compound and preparation method thereof |
| CN104327098A (en) * | 2014-10-21 | 2015-02-04 | 鲁南制药集团股份有限公司 | Cefetamet hydrochloride diisopropylamine salt |
| CN104327098B (en) * | 2014-10-21 | 2016-01-20 | 鲁南制药集团股份有限公司 | A kind of cefetamet diisopropylamine |
| CN110143972A (en) * | 2018-02-12 | 2019-08-20 | 罗欣药业(上海)有限公司 | A kind of Cefazedone sodium novel crystal form and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1903860B (en) | 2012-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1686117A (en) | Application of levoornidazole in preparation of anti anaerobic bacteria infection medicine | |
| CN101040867A (en) | Application of fucoidan in the preparation of medicine and health-care products for preventing and treating neurodegenerative diseases | |
| CN1931176A (en) | Aescin medicine composition and its prepn process and use | |
| CN1903860A (en) | Technology of preparing high purity cefotamei sodium by solvent process and its medical use | |
| CN105418641B (en) | It is a kind of former to develop quality Ceftriaxone Sodium and its pharmaceutical preparation | |
| WO2021228008A1 (en) | Cefuroxime magnesium compound, composition, preparation method therefor and use thereof | |
| WO2021228009A1 (en) | Piperacillin magnesium compound, composition, preparation method and use | |
| CN101143871B (en) | Cephalosporin derivative | |
| CN102574840B (en) | R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and l-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same | |
| CN101434611B (en) | Nitrogen heterocyclic ring substituted antibiotic, and preparation method and use thereof | |
| CN102552198B (en) | Cefcapene pivoxil hydrochloride hydrate composition tablets | |
| CN1107501C (en) | Albendazole emulsion | |
| CN1919847A (en) | Novel hydrochloride compound and use thereof | |
| CN101049312A (en) | Composition of medication, preparation method and application | |
| CN100516071C (en) | Amino butanetriol salt of cephalosporin compounds and preparing method | |
| CN101210021A (en) | Cephalosporin compounds | |
| CN1718183A (en) | Neo-garcinolic acid prepn. for injection use, prepn. method and use thereof | |
| RU2414899C1 (en) | Medications for treatment of disseminated sclerosis | |
| KR101142582B1 (en) | ?-lactamase-resistant cephalosporin ester compounds and salts of thereof | |
| CN104744447B (en) | Legalon rosemary acid esters and its production and use | |
| US20140128359A1 (en) | N-Heterocyclic Substituent-Containing Antibiotic, Preparation and Use Thereof | |
| CN102617605B (en) | Ceftriaxone sodium compound and preparation method thereof | |
| CN1297273C (en) | Pyrroloquinoline containing composition for enriching zinc and reducing plumbum | |
| CN1167421C (en) | Medicine composition containing pyrroloquinolinequinone for treating saturnism | |
| CN1861599A (en) | Quinone carboxylic acid kind derivant, it preparation process and medicine application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 610051 No. 18 Banqiao Road, Chengdu, Sichuan Patentee after: Zhejiang Haisen Pharmaceutical Co.,Ltd. Patentee after: Hainan Yi Shun Pharmaceutical Co.,Ltd. Address before: 610051 No. 18 Banqiao Road, Chengdu, Sichuan Patentee before: Zhejiang Haisen Pharmaceutical Co.,Ltd. Patentee before: HAINAN HAOCHUANG PHARMACEUTICAL Co.,Ltd. |
|
| DD01 | Delivery of document by public notice |
Addressee: Liu Qinglian Document name: payment instructions |
|
| DD01 | Delivery of document by public notice | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120118 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |